Molecular biomarker-guided anti-angiogenic targeted therapy for malignant glioma

J Cell Mol Med. 2019 Aug;23(8):4876-4882. doi: 10.1111/jcmm.14417. Epub 2019 Jun 18.

Abstract

Despite aggressive multimodality treatment, the prognosis of glioma, especially malignant glioma, remains very poor. After decades of effort, anti-angiogenic therapy has become an important method of cancer treatment in addition to surgery, radiotherapy and chemotherapy. Although the performance of anti-angiogenic therapy in colorectal cancer is good, its performance in malignant glioma remains unsatisfactory. Several phase III clinical trials showed no overall survival benefits. To solve this problem, the division of patients into groups based on their molecular biomarkers is an important step. This paper provides current insights into anti-angiogenic drugs undergoing clinical trials and discusses the potential of molecular biomarkers to guide glioma diagnosis.

Keywords: anti-angiogenic; biomarkers; glioma; molecular; therapy.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / pharmacology
  • Angiogenesis Inhibitors / therapeutic use*
  • Bevacizumab / pharmacology
  • Bevacizumab / therapeutic use
  • Biomarkers, Tumor / blood
  • Biomarkers, Tumor / metabolism*
  • Brain Neoplasms / classification
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / enzymology
  • Brain Neoplasms / metabolism
  • Glioma / classification
  • Glioma / drug therapy*
  • Glioma / enzymology
  • Glioma / metabolism
  • Humans
  • Indoles / pharmacology
  • Indoles / therapeutic use
  • Molecular Targeted Therapy
  • Prognosis
  • Snake Venoms / pharmacology
  • Snake Venoms / therapeutic use

Substances

  • Angiogenesis Inhibitors
  • Biomarkers, Tumor
  • Indoles
  • Snake Venoms
  • Bevacizumab
  • Cilengitide
  • enzastaurin